083-Lung Cancer PET Imaging Phase 1b study Before & After Chemotherapy

• Research type

  Research Study

• Full title

  A Multicenter Phase Ib Trial to Measure [18F]- Fluorodeoxyglucose Uptake by Positron Emission Tomography in Stage IIIB and IV Non-Small Cell Lung Cancer Before and After Chemotherapy With Gemcitabine and Cisplatin or Carboplatin

• IRAS ID

  9072

• Sponsor organisation

  Merck & Co, Inc

• Eudract number

  2008-003119-11

• Research summary

  Better methods are needed in clinical trial to determine whether new treatments for lung cancer are working. In a type of imaging scan called FDG-PET, [18Fflurodeoxyglucose (FDG) uptake by tumour tissue holds promise as a type of scanning method which shows an early marker showing the relationship with Progression Free Survival (PFS) and Overall Survival (OS). Basically, FDG-PET scans may indicate response to treatment before conventional scans/images would detect response.The study is a phase 1b study which aims to investigate whether FDG-PET scans (type of imaging scans) of the primary tumour is a fast indicator of treatment response in patients with Non-Small Cell Lung Cancer (NSCLC) treated with standard therapy - Gemcitabine and Cisplatin or Gemcitabine and Carboplatin. The chemotherapy is standard care.

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  09/H1008/5

• Date of REC Opinion

  1 May 2009

• REC opinion

  Further Information Favourable Opinion